Canine insulinoma is one of those conditions the NAVLE loves to test because it hits multiple systems at once — endocrine, neuro, emergency medicine, surgery. The presentation is dramatic, the diagnosis has a specific algorithm, and the management decisions are high-stakes. Get the logic down and this becomes a reliable point-getter.
What You're Dealing With
Insulinomas arise from the beta cells of the islets of Langerhans in the pancreas. They're functional — meaning they secrete insulin. The problem is they keep secreting it even when blood glucose falls, because the normal negative feedback loop is broken. Neoplastic beta cells don't respond to hypoglycemia the way normal beta cells do.
The result is progressive, inappropriate hyperinsulinemia driving profound hypoglycemia. The brain, an obligate glucose consumer with minimal glycogen reserves, takes the hit hardest.
One number to know cold: >95% of canine insulinomas are malignant. This is the opposite of the human situation, where the vast majority are benign. About 45–55% of dogs already have metastatic disease at diagnosis, most commonly to regional lymph nodes and liver.
Signalment: middle-aged to older dogs, mean diagnosis around 9 years. Large and medium breeds are overrepresented — German Shepherds, Irish Setters, Boxers, Golden Retrievers, Labs, Standard Poodles. No sex predilection in dogs.
Whipple's Triad
Every insulinoma question on the NAVLE orbits around Whipple's triad. Know it cold.
| Component | What It Means |
|---|---|
| 1. Clinical signs of hypoglycemia | Weakness, ataxia, seizures, collapse, disorientation |
| 2. Documented low blood glucose | <50 mg/dL (<2.8 mmol/L) during an episode |
| 3. Resolution with glucose | Signs resolve after glucose administration or feeding |
The clinical pattern is episodic. Signs come on during fasting, exercise, or excitement. Owners often describe the dog as "spacy" or "not themselves" — vague early, then progressively more alarming. Feeding often makes things better, which is the giveaway. When you hear "episodic collapse or seizures that improve after eating," insulinoma is the top differential until proven otherwise.
The Diagnostic Workup
The diagnosis rests on two simultaneous lab values: hypoglycemia + inappropriately elevated or normal insulin. A normal insulin level is still "inappropriate" when glucose is critically low — insulin should be suppressed. Finding it normal or high at that moment is the red flag.
The amended insulin:glucose ratio (AIGR) was a classic formula tested on older boards:
AIGR = [Serum insulin (μU/mL) × 100] ÷ [Blood glucose (mg/dL) – 30]
An AIGR ≥30 is consistent with insulinoma. If blood glucose is ≤30 mg/dL, use 1 as the denominator to avoid division by zero. This ratio is less commonly used now that direct insulin measurement at the time of hypoglycemia is preferred, but it shows up on boards periodically.
Critical rule: draw blood for insulin measurement BEFORE giving dextrose. Once you treat the hypoglycemia, you've lost the diagnostic window. Stabilize the patient enough to draw the sample, then treat.
Blood glucose <60 mg/dL after a fast is suspicious. Most dogs with insulinoma become hypoglycemic within 12–24 hours of food withdrawal, but a normal glucose at presentation does NOT rule out insulinoma.
Imaging
Contrast-enhanced CT is the gold standard for both tumor detection and staging. Triple-phase CT angiography catches insulinomas as hypervascular, arterially enhancing lesions. Sensitivity is around 71%. Ultrasound is more accessible but has sensitivity of only 36–56% — insulinomas are usually small (<2.5 cm), and ultrasound misses lymph node metastases reliably. Use CT when you can, especially before surgery.
TNM staging matters here because it directly affects prognosis:
- Stage I: tumor confined to pancreas, no metastasis → median survival ~18 months with surgery
- Stage II: regional lymph node metastasis → survival drops significantly
- Stage III: distant metastasis (liver, peritoneum) → median survival ~1 month post-surgery
Emergency Management of Acute Hypoglycemia
When a dog comes in seizing from hypoglycemia, the instinct is to slam dextrose. Fight that instinct. Rapid, high-concentration dextrose boluses stimulate further insulin release from the tumor — you get a rebound crisis. The goal is to stop the seizures and control signs, not to normalize blood glucose rapidly.
Hospital protocol:
- Draw blood for insulin level before treating
- Give 50% dextrose diluted 1:4 with saline at 0.5–1 mL/kg IV slowly over 5–10 minutes
- Start dextrose CRI (2.5–5% dextrose in fluids) to maintain glucose
- If seizures persist after glucose correction, diazepam 0.5–1 mg/kg IV
- Monitor glucose frequently; adjust CRI rate
For home emergencies: rub corn syrup or sugar solution on the buccal mucosa, offer a small meal when the dog can swallow, then get to a clinic immediately.
Surgical Treatment
Surgery is the treatment of choice. Even in dogs with metastatic disease, surgical debulking reduces the insulin-secreting tumor burden and improves quality of life and survival time compared to medical management alone.
Options: partial pancreatectomy (preferred for solitary masses) or tumor enucleation for small, well-encapsulated tumors. Resection of hepatic and lymph node metastases is done when possible.
Perioperative management is critical. Tumor manipulation can dump a massive insulin bolus. Run dextrose-containing fluids throughout surgery and monitor glucose continuously. Common postoperative complications: pancreatitis (most common), transient hyperglycemia or outright DM (from downregulation of the remaining beta cell mass), and persistent hypoglycemia if microscopic disease remains.
Medical Management
Medical management is used when surgery is declined, when metastatic disease is too extensive for meaningful debulking, or when hypoglycemia recurs after surgery.
| Drug / Strategy | Mechanism | Notes |
|---|---|---|
| Frequent small meals | Maintains steady glucose without spiking insulin | 4–6 small meals/day; high protein, fat, complex carbs; avoid simple sugars; restrict exercise |
| Diazoxide | Inhibits insulin secretion by opening K+ channels on beta cells, blocking calcium influx needed for exocytosis; also promotes hepatic glycogenolysis | First-line medical drug; ~70% response rate; start 5 mg/kg PO q12h, can go up to 30 mg/kg q12h; GI side effects common |
| Prednisone | Promotes gluconeogenesis and antagonizes insulin at tissue level (peripheral insulin resistance) | 0.5–2 mg/kg/day; often added when diazoxide alone is insufficient; long-term use carries typical corticosteroid side effects |
| Octreotide | Somatostatin analog; inhibits insulin secretion via somatostatin receptors on tumor cells | Variable response in dogs; expensive; SQ injection; reserved for refractory cases; not all insulinomas express somatostatin receptors |
Prognosis
Prognosis is guarded because >95% are malignant and most dogs have or will develop metastasis. That said, surgery buys meaningful time. Stage I dogs treated surgically have median survival around 18 months. Stage II/III dogs have much shorter disease-free intervals — sometimes as little as 1 month before hypoglycemia recurs.
Postoperative normoglycemia or transient hyperglycemia is a better prognostic sign than persistent hypoglycemia, which signals residual tumor or microscopic disease. The most important prognostic factor is TNM stage at the time of surgery — which is exactly why CT staging before the OR matters.